Can a daily pill keep brain lymphoma at bay after remission?

NCT ID NCT06940791

Recruiting now Disease control Sponsor: Kyorin University Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receive either tirabrutinib or a placebo, and researchers will compare how long it takes for the disease to progress. The goal is to see if this maintenance approach can delay or prevent relapse without the need for whole-brain radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirabrutinib, an oral drug taken daily, compared against a placebo
What this could lead to: If effective, tirabrutinib maintenance could become a standard way to keep primary CNS lymphoma in remission longer, potentially delaying or preventing relapse without the need for whole-brain radiation.
What could go wrong: This is a phase II trial with a modest number of participants, so results may not be definitive. Tirabrutinib can cause side effects, and the benefit over placebo is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Kyorin University Hospital
RECRUITING

Tokyo, 181-8611, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.